Table 2.
Impact of sera on CAR T cell function.
| Serum | Medium | Cell expansion | Outcomes | Ref |
|---|---|---|---|---|
| 10% FBS | RPMI-1640 | Greatest expansion in 10% FBS+RPMI-1640 compared to other conditions |
5% HS vs 2% Phx in Optimizer • enhanced lentiviral-mediated gene expression in Phx • enhanced GD2 CAR T cell activity in vivo in Phx |
(28) |
| 2% Phx | ||||
| 5% HS | X-VIVO15 | |||
| 2% Phx | ||||
| 5% HS | Optimizer | |||
| 2% Phx | ||||
| 10% FBS | RPMI-1640 + Click’s medium |
Comparable in 10% serum conditions (lower expansion in FBS if % serum is reduced) |
• HPL-maintained T cells had a less-differentiated phenotype in vitro
• HPL-cultured CAR T cells exhibited enhanced proliferation upon in vitro antigen stimulation • HPL-expanded CD19 CAR and PSCA CAR T cells exhibited superior in vivo anti-tumor effect with prolonged T cell persistence |
(33) |
| 10% AB serum | ||||
| 10% HPL | ||||
| (–) | X-VIVO 15 | Comparable | CD19 CAR T cells cultured in 1B2H (no serum) showed better in vivo anti-tumor effect compared to the ones in 1B2H (5% HS) | (21) |
| 5% HS | ||||
| (–) | 1B2H (+ glucose & galactose) | |||
| 5% HS |